- Home
- WTI vs ZNTL Comparison
WTI vs ZNTL Comparison
Compare WTI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTI | ZNTL |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.3M | 468.9M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WTI | ZNTL |
|---|---|---|
| Price | $3.81 | $4.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | ★ 8.1M | 4.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $487,096,000.00 | N/A |
| Revenue This Year | $11.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $1.13 |
| 52 Week High | $4.49 | $6.95 |
Technical Indicators
Market Signals| Indicator | WTI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 54.97 |
| Support Level | $1.71 | $3.75 |
| Resistance Level | $4.49 | $4.34 |
| Average True Range (ATR) | 0.29 | 0.38 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 60.06 | 28.72 |
Price Performance
Historical ComparisonAbout WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.